MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?

As the so-called price maintenance premium (PMP) for on-patent drugs will see a major reduction in its scope in April 2018, many products are anticipated to lose eligibility on a series of new restrictions, particularly one dubbed the “three year/third...read more